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Background: Testicular germ cell tumours (TGCTs) are the most common malignancy in young men aged
18–35 years. They are clinically and histologically subdivided into seminomas and non-seminomas. Cadherins are
calcium-dependent transmembrane proteins of the group of adhesion proteins. They play a role in the stabilization
of cell-cell contacts, the embryonic morphogenesis, in the maintenance of cell polarity and signal transduction.
N-cadherin (CDH2), the neuronal cadherin, stimulates cell-cell contacts during migration and invasion of cells and
is able to suppress tumour cell growth.
Methods: Tumour tissues were acquired from 113 male patients and investigated by immunohistochemistry, as
were the three TGCT cell lines NCCIT, NTERA-2 and Tcam2. A monoclonal antibody against N-cadherin was used.
Results: Tumour-free testis and intratubular germ cell neoplasias (unclassified) (IGCNU) strongly expressed
N-cadherin within the cytoplasm. In all seminomas investigated, N-cadherin expression displayed a
membrane-bound location. In addition, the teratomas and yolk sac tumours investigated also differentially
expressed N-cadherin. In contrast, no N-cadherin could be detected in any of the embryonal carcinomas and
chorionic carcinomas examined. This expression pattern was also seen in the investigated mixed tumours
consisting of seminomas, teratomas, and embryonal carcinoma.
Conclusions: N-cadherin expression can be used to differentiate embryonal carcinomas and chorionic carcinomas
from other histological subtypes of TGCT.
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Testicular germ cell tumours (TGCTs) are the most
common malignancy in young men aged 18–35 years.
The incidence of TGCT has been constantly increasing
over the last 40 years [1]. TGCTs are clinically and
histologically subdivided into seminomas and non-semi-
nomas. Non-seminomas can be further subdivided into
embryonal carcinomas (EC), teratomas (TER), yolk
sac tumours (YS) and chorionic carcinomas (CC) [2].
Seminomas and non-seminomas originate from intra-
tubular germ cell neoplasia (IGCNU) [3].
Cadherins are Ca2+-dependent transmembrane glyco-
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reproduction in any medium, provided the orMore than 80 different members constitute the group of
cadherins, such as the well-investigated epithelial, neural
and placental cadherins [4]. Cadherins are considered to
play a major role in cell-cell contacts, in the develop-
ment of different organs and also in the genesis of
tumours. Furthermore, they function as metastasis-
suppressing proteins [5]. Decreased cadherin expression
is normally found in cancers and is associated with an
increased rate of metastasis [6].
N-cadherin (CDH2), the neuronal cadherin, is a 140 kD
protein and was first identified in mouse brain tissue [7].
It plays an important role in migration, differentiation,
embryonic development and metastatic behaviour of
tumour cells [8].The function of N-cadherin is dependent
on its association with the actin-cytoskeleton, which is
mediated through interactions between the C-terminal
region of N-cadherin and the cytoplasmic catenin proteinsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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different normal tissues [11]. Furthermore, N-cadherin
expression could be identified in benign and malignant
neoplastic tissues of epithelial and mesenchymal origin
[12–17]. In the present study we analysed the expression
of N-cadherin in testicular germ cell tumours.
Methods
Tissue samples of primary TGCT
Tumour tissues from orchiectomy specimens were
acquired from 113 male patients from the University
Medical Centre Göttingen, Germany (mean age = 33.86
years). Tumours were classified and staged on the basis of
the WHO classification [18]. In the present study a number
of 123 blocks have been tested. Investigated cases included
IGCNU (n=20), seminomas (n= 77), embryonal carcinomas
(n= 40), teratomas (n=17), chorionic carcinomas (n=4), and
yolk sac tumours (n=11). One section was made of each
tumour per 0.5 cm tumour diameter. Tumour tissues from
each testis were immediately fixed in formalin and embed-
ded in paraffin. In addition, normal testis specimens were
analysed (n=28, mean age 35.82 ± 12.41). Ethical approval
for using the human material in the present study was
obtained from the Ethics Committee of the University
Medical Centre Göttingen.
Two independent investigators evaluated all tissue
sections considering membranous and cytoplasmic
N-cadherin staining and using an immunoreactive staining
score (IRS). The percentage of positively stained cells was
first categorized using a 0–4 scoring system: Score 0 = 0%
positive cells, score 1= less than 10% positive cells, score
2 = 10–50% positive cells, score 3 = 51–80% positive cells
and score 4 = > 80% positive cells. The intensity of staining
was evaluated on a graded scale (0 = negative; 1 = weak;
2 = intermediate; 3 = strong). For the final IRS, the scores
of intensity and staining were multiplied and the mean
value per patient was calculated.Figure 1 N-cadherin expression in normal testis and IGCNU: Strong c
expression is seen in the normal testis (A; x200). In representative tissu
arrow) and a cytoplasmic (white arrow) is seen (B; x200). N-cadherin is not
cells (A - B).Immunohistochemistry
Immunohistochemical reactions were performed on 5-μm
formalin-fixed and paraffin-embedded testis tissue
sections of the testis. The sections were incubated in
citrate buffer (pH 6). For primary antibodies the sections
were incubated for 30 minutes at room temperature with
monoclonal antibody against N-cadherin diluted at 1:50
(DAKO, Hamburg, Germany). Thereafter the sections
were incubated with the biotinylated secondary antibody
and the streptavidin alkaline phosphatase (REAL, Dako,
Hamburg, Germany). Fast red (Dako) was applied to
visualise the sites of immunoprecipitations. Tissue
samples were analysed by light microscopy after counter-
staining with Meyer’s haematoxylin.
Culture of TGCT cell lines
The human TGCT cell lines used in the present study
were NCCIT (CRL 2073, teratocarcinoma), NTERA-2
(CRL 1973, embryonal carcinoma) (both cell lines from
American Type Culture Collection, Manassas, VA, USA)
and Tcam2 (seminoma) (Department of Developmental
Pathology, University of Bonn Medical School, Germany).
The explored cell lines were cultured in HEPES-buffered
RPMI-1640 (Biochrom, Berlin, Germany) supplemented
with foetal calf serum (FCS, 10%; CC Pro, Neustadt,
Germany), penicillin (100 IU/ml; Sigma, Munich,
Germany), streptomycin (100 μg/ml; Sigma), and
L-glutamine (2 mM; Biochrom, Berlin, Germany). The
incubation temperature was 37°C in a humid atmosphere
with 5% carbon dioxide in the air. Cytospins were
prepared for the immunohistochemical analysis.
Results
Immunohistochemical staining for N-cadherin in
tumour-free testis, IGCNU and invasive TGCT
Tumour-free testes exhibit strong cytoplasmatic expression
of N-cadherin in all spermatogenesis and Sertoli cellsytoplasmic (white arrow) and a weak membranous (black arrow)
es of IGCNU, a more pronounced membranous expression (black
detectable in sperms and cells of the interstitium, including Leydig
Figure 2 N-cadherin expression in seminomas: Seminomas express N-cadherin (white arrow); strong N-cadherin expression in IGCNU is
seen next to the tumour (black arrow) (A; x100). The seminoma cells demonstrate a strong membrane-bound (white arrow) and a weak
cytoplasmic (black arrow) expression of N-cadherin (B; x400).
Figure 3 N-cadherin expression in teratoma and yolk sac tumour: Teratoma: N-cadherin is differentially expressed in teratomas.
Tumour components with primitive neuronal elements display N-cadherin expression (white arrow, A+C; x40). Tumour components with
connective tissue are negative (black arrow, B+D; x200). Yolk sac tumour: Normal testis and IGCNU (white arrow) are positive for N-cadherin
expression. The tumour cells within the yolk sac tumour also show a strong N-cadherin expression (black arrow, E; x100).
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Figure 4 N-cadherin expression in embryonal carcinoma and chorionic carcinoma: Embryonal carcinoma: Normal testis and IGCNU
showing N-cadherin expression (white arrow). In contrast, the embryonal carcinoma cells do not show any expression of N-cadherin (black
arrows, A; x40, B; x200, C; x400). Even mixed tumours with embryonal carcinoma are negative for N-cadherin (black arrow), whereas seminoma
shows N-cadherin expression (white arrow, D; x100). Chorionic carcinoma: Tumour cells and syncytiotrophoblastic cells do not show N-cadherin
expression (white arrow). Adjacent tumour cells (yolk sac tumour components) are positive for N-cadherin expression and show membranous
and cytoplasmic staining (black arrow, E; x40, F; x200).
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tium and Leydig cells are completely negative for
N-cadherin (0/28). IGCNU strongly express N-cadherin
within the cytoplasm and at the membrane (20/20), with a
more pronounced cytoplasmic expression (IRS 10.8 ±1.88)
(Figure 1B).
All examined seminomas show a membrane-bound
N-cadherin expression, with the expression located cyto-
plasmatically in only some cases (IRS 9.38 ± 2.59)
(Figure 2A + B).
All investigated teratomas show diverse N-cadherin
expression pattern. Areas with primitive neuronal elements
display positive N-cadherin staining (IRS 7.11 ± 0.99).Other tumour components like hyaline cartilage or con-
nective tissue are negative for N-cadherin expression
(Figure 3A-D). Yolk sac tumours show a strong N-cadherin
expression pattern within the tumour cells. The expression
is located cytoplasmatically or bound to the membrane
(IRS 9.90 ± 0.94) (Figure 3E).
In contrast, N-cadherin can not be detected in any of the
embryonal carcinomas examined; this is also seen in the
investigated mixed tumours consisting of seminomas, tera-
tomas, and embryonal carcinoma (Figure 4A-D). Chorionic
carcinoma components within malignant germ cell
tumours prove also to be negative for N-cadherin expres-
sion (Figure 4E-F).
Table 1 Immunreactive score and localization of
N-cadherin expression (mb = membrane bounded;
c = cytoplasmically) within the investigated testicular
neoplasias; note that one tumour sample can obtain
more than one histological tumour type
Tumour type n IRS Localisation of
N-cadherin expression
normal testis 28 10.52 ± 1.96 c > mb
IGCNU 20 10.8 ± 1.88 c > mb
seminoma 77 9.38 ± 2.59 mb > c
embryonal carcinoma 40 0 none
teratoma 17 7.11 ± 0.99 c > mb
choriocarcinoma 4 0 none
yolk sac tumour 11 9.90 ± 0.94 c > mb
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N-cadherin expression in TGCT cell lines
The tumour cell line NCCIT originating from a terato-
carcinoma shows strong cytoplasmic N-cadherin expression
based on the positive expression in teratomas in vivo. In
addition, the Tcam2 cell line originating from a semi-
noma, also show N-cadherin expression comparable
to the in vivo results. NTERA-2 orginating from an
embryonal carcinoma, on the other hand, does not show
N-cadherin expression as it does in the embryonal
carcinoma in vivo (Figure 5A-C).
Discussion
In young men aged 18 to 35 years, testicular germ cell
tumours are the most common malignant tumours.
TGCT can be divided into the two groups of semi-
nomas and non-seminomas [1]. Differentiating between
seminomas and non-seminomas and also mixed germ
cell tumours is important because of their different
prognosis and therapy [2].
N-cadherin plays a crucial role in organ development
and is usually expressed in neuronal tissue [19]. It could
be shown that a non-tissue-specific expression of N-
cadherin in tumours plays a crucial role for cell migra-
tion, invasion and metastases [20]. This process is also
essential in embryonic development and is calledFigure 5 N-cadherin expression in TGCT cell lines: N-cadherin shows
teratocarcinoma (A; x200); in contrast no expression is seen in the NT
positive N-cadherin expression is also seen in the Tcam2 cell line representepithelial-mesenchymal transition (EMT) [21]. The EMT
stimulates the mobility and invasive capacity of tumour
cells and it is associated with tumour progression [22,23]
as well as the development of chemotherapy resistance
[24,25]. In addition, not only a non-tissue-specific
expression of N-cadherin, but also the switch from dif-
ferent cadherins to N-cadherin are connected with a
poor prognosis [26,27].
In the present study we observed cytoplasmatic and
membranous N-cadherin expression in tumour-free testis,
IGCNU, seminomas, yolk sac tumours and in primitive
neuronal elements within teratomas. Loojenga et.al anda strong expression in the NCCIT cell line representing
ERA-2 cell line representing embryonal carcinoma (B; x200). A
ing a seminoma (C; x200).
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seminomas in most cases [28,29]. The positive N-cadherin
expression in our investigation could be an indication of
EMT at least in seminomas. Interestingly, N-cadherin was
not expressed in embryonic carcinomas and in components
of chorionic carcinoma, as we could show in the present
study. In contrast, it could be shown that E-cadherin is
expressed in embryonic carcinomas [28]. Hart et al.
described a model of tumorgenesis in testis germ cell
tumours [30]. In this model non-seminomatous germ cell
tumours can arise from IGCNU or from seminomas. It
seems that malignant germ cell tumours of the testis with-
out N-cadherin but with positive E-cadherin expression
show a differentiation into an embryonic carcinoma or
chorionic carcinoma. It would be interesting to see whether
the expression of N-cadherin is accompanied by the activa-
tion of a corresponding pathway or influence a specific
differentiation. Such an analysis would possibly offer
insights into the relation between N-cadherin expression
and behaviour of the tumour.
Several immunohistochemical markers are known
for the differential diagnosis of malignant germ cell
tumours. Seminomas are usually positive for placental
alkaline phosphatise (PLAP) and CD117 (c-kit) [31–33].
OCT 4 is expressed in seminomas and embryonal
carcinomas [34]. Immunohistochemical expression of
alpha fetoprotein (AFP) can be used for the diagnosis of
yolk sac tumours [35]. Chorionic carcinoma shows an
expression of human chorionic gonadotropin [36]. For
embryonal carcinoma CD30 positivity in connection
with the expression of CD117 usually verifies the diag-
nosis. Thus N-cadherin expression correlates with the
expression pattern of immunohistochemical markers of
malignant germ cell tumours such as CD117, PLAP and
AFP. Interestingly CD30 and ßHCG are conversely
expressed to N-cadherin.Conclusions
N-cadherin expression can be used to differentiate
embryonal carcinomas and chorionic carcinomas from
other histological subtypes of TGCT. Thus, loss of
N-cadherin possibly influences the differentiation of malig-
nant germ cell tumours.Competing interests
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